George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Meeting

9 Mar 2020 11:07

RNS Number : 4455F
4d Pharma PLC
09 March 2020
 

4D pharma plc

 

("4D pharma" or the "Company")

 

Result of General Meeting

 

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutic products, announces that, at the General Meeting held earlier today to enable the proposed issue of a total of 44,000,000 New Ordinary Shares in connection with the Placing and Subscription to raise gross proceeds of £22 million, all Resolutions were duly passed.

 

Further to the Result of Placing announcement made on 18 February 2020, 27,176,920 Subscription Shares and 16,823,080 Placing Shares will be issued. The total number of New Ordinary Shares to be issued pursuant to the Subscription and Placing remains unchanged.

Application has been made to the London Stock Exchange for the 44,000,000 New Ordinary Shares to be admitted to trading on AIM and it is expected that Admission will occur and dealings commence at 8.00 a.m. tomorrow, 10 March 2020.

Total Voting Rights

Following Admission, the Company will have 109,493,842 Ordinary Shares in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. There Company holds no Ordinary Shares in treasury.

Block Admission

A block admission has been made in respect of 22,000,000 shares which may arise from the exercise of Warrants issued in connection with the Fundraising ("Warrant Shares") under the scheme name '4D March 2020 Warrants'. Admission of the block listed shares will also take effect on 10 March 2020. For the avoidance of doubt, the Warrants themselves will not be admitted to Trading on AIM. Each Warrant entitles the holder to subscribe for one Ordinary Share at a price of 100 pence at any time up to 10 March 2025.

 

Definitions

 

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to them in the announcement made by the Company on 18 February 2020 to announce the launch of the Placing.

 

 

For further information please contact:

4D

 

Duncan Peyton, Chief Executive Officer

ir@4dpharmaplc.com

+ 44 (0)113 895 0130

 

 

N+1 Singer - Nominated Adviser, Joint Bookrunner and Joint Broker

+44 (0) 20 7496 3000

Aubrey Powell / Justin McKeegan / Alex Bond (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

 

Bryan Garnier & Co. Limited - Joint Bookrunner and Joint Broker

+44 (0)20 7332 2500

Dominic Wilson / Phil Walker

 

Chardan - US Placing Agent

David Lederman (Equity Capital Markets)

+1 646 465-9011

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROMJLMBTMTMMBFM
Date   Source Headline
18th Mar 20204:39 pmRNSPrice Monitoring Extension
18th Mar 20207:49 amRNSDirector/PDMR Shareholding
17th Mar 20207:00 amRNSAdditional Interim Clinical Data
16th Mar 20207:00 amRNSParticipation in Chardan Conference
11th Mar 20209:49 amRNSHolding(s) in Company
11th Mar 20207:00 amRNSHolding(s) in Company
9th Mar 202011:07 amRNSResult of Meeting
21st Feb 20202:25 pmRNSHolding(s) in Company
19th Feb 20202:06 pmRNSPosting of Circular
18th Feb 20206:28 pmRNSResult of Placing
18th Feb 20207:00 amRNSLaunch of Placing
7th Feb 20203:18 pmRNSHolding(s) in Company
6th Jan 20207:00 amRNSClinical Update
4th Dec 201911:22 amRNSHolding(s) in Company
29th Nov 201911:19 amRNSHolding(s) in Company
8th Nov 201911:27 amRNSHolding(s) in Company
6th Nov 20197:00 amRNSClinical Observations from MRx0518
5th Nov 20195:36 pmRNSHolding(s) in Company
4th Nov 201912:22 pmRNSHolding(s) in Company
4th Nov 201912:04 pmRNSHolding(s) in Company
17th Oct 201911:17 amRNSHolding(s) in Company
15th Oct 20192:51 pmRNSHolding(s) in Company
8th Oct 20197:00 amRNSCollaboration with MSD
30th Sep 20197:00 amRNSInterim Results
27th Sep 201912:23 pmRNSHolding(s) in Company
26th Sep 201911:40 amRNSHolding(s) in Company
23rd Sep 20197:00 amRNSPublication of data on neurodegenerative disease
20th Sep 20191:28 pmRNSHolding(s) in Company
20th Sep 20191:19 pmRNSHolding(s) in Company
20th Sep 201911:20 amRNSHolding(s) in Company
27th Aug 20197:00 amRNSAppointment of NED
25th Jul 20197:00 amRNSOncology Programmes Update
8th Jul 20193:51 pmRNSHolding(s) in Company
8th Jul 20197:00 amRNSClinical Update
1st Jul 20197:00 amRNSChange of Adviser
20th Jun 201910:38 amRNSResult of AGM
3rd Jun 20197:00 amRNS4D presents MRx0518 combination study at ASCO
30th May 20197:00 amRNSDirector/PDMR Shareholding
28th May 20192:50 pmRNSAnnual Report and Notice of AGM
23rd May 20197:00 amRNSDirector/PDMR Shareholding
22nd May 20197:00 amRNSDirector/PDMR Shareholding
21st May 20197:00 amRNSFinal Results
16th May 20197:00 amRNS4D Presents Phase Ib Clinical Data on Thetanix®
13th May 20198:00 amRNSParticipation in Conferences
29th Apr 20197:00 amRNSClinical Update - MRx0518 oncology programmes
14th Mar 20197:00 amRNSDirector/PDMR Shareholding
13th Mar 20199:08 amRNSDirector/PDMR Shareholding
8th Mar 20197:00 amRNSParticipation in Microbiome Conference
29th Jan 20197:00 amRNSPublication of data in connection with MRx0518
7th Jan 20197:00 amRNSCollaboration with MD Anderson Cancer Center

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.